Corporate Banner
Satellite Banner
Technology Networks Header
Monday, July 28, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
GE Healthcare Launches Xuri™ IL-2 Growth Factor
Thursday, May 15, 2014
Xuri™ IL-2 for the reliable activation and expansion of T-lymphocytes.

BioSpring Selects GE Healthcare Life Sciences OligoProcess™
Thursday, May 15, 2014
Next-generation OligoProcess system has potential to help pharmaceutical industry save time and money.

Interpack 2014: New Syringes from SCHOTT for Use in Infusion Therapy
Tuesday, May 13, 2014
Large-format 20 ml TopPac syringe for syringe pumps.

New Solid Phase Extraction Technology for Bioanalysis from Thermo Scientific
Tuesday, May 13, 2014
Designed to provide robust, reproducible extractions at low elution volumes.

Apitope Initiates Preclinical Development of Peptide Therapy, ATX-F8-117
Saturday, May 10, 2014
Peptide therapy for the treatment of Factor VIII intolerance.

Interpack 2014: Sterile and Ready to Use Packaging by SCHOTT
Thursday, May 08, 2014
SCHOTT’s sterile, ready to use vials adaptiQ™ will be on display at Interpack.

Gallus BioPharmaceuticals Utilizes ambr15 Micro Bioreactor
Tuesday, May 06, 2014
To rapidly optimize process development of novel antibodies and biosimilars.

Quantitative Imaging Mode of the NanoWizard 3
Thursday, May 01, 2014
JPK Instruments reports on the use of the Quantitative Imaging mode for tissue engineering studies at Niigata University.

Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System
Friday, April 25, 2014
To accelerate their process scale-up of biological therapies and vaccines.

<< 1 2 3 4 5 6 7 >>
Showing Results 31 - 40 of 445
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv